Eliem Therapeutics, Inc. (ELYM) Tops Q4 EPS by 4c

Eliem Therapeutics, Inc. (NASDAQ: ELYM) reported Q4 EPS of ($0.29), $0.04 better than the analyst estimate of ($0.33).

For earnings history and earnings-related data on Eliem Therapeutics, Inc. (ELYM) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group
• Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'